Of the 52 new drugs approved in the past decade, 21% were categorized as first in class, but more innovations are needed for skin diseases with unmet therapeutic needs, the authors said.
Dual antiplatelet therapy initiated up to 72 hours post-stroke cuts the risk for recurrent stroke but comes with increased bleeding risk, new data from the INSPIRES trial showed.